As part of its commitments under the newly reauthorized Prescription Drug User Fee Act (PDUFA VII), the FDA has launched the Rare Disease Endpoint Advancement (RDEA) pilot that will test a new meeting system to help sponsors of rare disease clinical trials develop efficacy endpoints.
Source: Drug Industry Daily